AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2023
Jan 6, 2023
33483_dirs_2023-01-06_25a4581d-edaa-4da8-ab32-e3437c025cfd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2023-01-04
Reporting Person: Johnston Lloyd P. (Chief Operations Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-04 | Common Stock | S | 6381 | $1.1337 | Disposed | 268918 | Direct |
| 2023-01-04 | Common Stock | S | 11 | $1.1401 | Disposed | 268907 | Direct |
| 2023-01-05 | Common Stock | S | 3372 | $1.1293 | Disposed | 265535 | Direct |
| 2023-01-05 | Common Stock | S | 20 | $1.1104 | Disposed | 265515 | Direct |
Footnotes
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
More from Cartesian Therapeutics, Inc.
Capital/Financing Update
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8